Foresite Capital Management II’s Adaptimmune Therapeutics ADAP Stock Holding History

Foresite Capital Management II’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-700,000	Closed	-$4.03M	–	9
2018 Q4	$4.03M	Buy	700,000 +200,000	+40%	+$1.48M	2.13%	7
2018 Q3	$6.78M	Sell	500,000 -200,000	-29%	-$2.1M	2.51%	7
2018 Q2	$8.31M	Buy	700,000 +300,000	+75%	+$3.74M	2.93%	7
2018 Q1	$4.49M	Buy	+400,000	New	+$3.5M	1.49%	8
2016 Q3	–	Sell	-1,054,864	Closed	-$8.6M	–	11
2016 Q2	$8.6M	Sell	1,054,864 -706,703	-40%	-$6.66M	5.88%	7
2016 Q1	$14.3M	Hold	1,761,567	–	–	7.01%	5
2015 Q4	$21.2M	Buy	1,761,567 +4,299	+0.2%	+$42.1K	7.12%	3
2015 Q3	$21M	Hold	1,757,268	–	–	6.39%	4
2015 Q2	$32.2M	Buy	+1,757,268	New	+$30.2M	11.3%	2

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Foresite Capital Management II's ADAP Position: Q1 2019 in Review

Foresite Capital Management II sold out of Adaptimmune Therapeutics (ADAP) in Q1 2019, closing a stake of 700,000 shares — an estimated $4.03M sold.

Foresite Capital Management II first reported a position in ADAP in Q2 2015 and held it in 9 quarters. The position peaked at $32.2M in Q2 2015. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

Foresite Capital Management II reported no remaining Adaptimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
Foresite Capital Management II sold 700,000 Adaptimmune Therapeutics shares in Q1 2019, an estimated $4.03M.
Foresite Capital Management II first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 9 quarters.
Foresite Capital Management II's Adaptimmune Therapeutics position peaked at $32.2M in Q2 2015.
68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on Foresite Capital Management II's 13F filing for Q1 2019, filed 14 May 2019.